NFKB1 and familial pancreatic carcinoma: To further support this observation, we examined the effect of pristimerin on the DNA-binding activity of NF-κB/p65 using a specific NF-κB/p65 ELISA and found pristimerin treatment resulted in a significant dose-dependent reduction in DNA-binding activity of NF-κB/p65 in all three pancreatic cancer cells (Fig. 6B).